INBRAIN Neuroelectronics is pioneering a revolutionary advancement in brain-computer technology, developing ultrathin graphene-based implants poised to transform neurological treatments.
Capitalising on a recent substantial funding boost, the company aims to expand its groundbreaking platform and enhance its capabilities in neurology. By leveraging sophisticated AI and cutting-edge materials technology, INBRAIN is set to redefine neural interface therapies.
INBRAIN Neuroelectronics Secures New Funding
INBRAIN Neuroelectronics, a leading force in brain-computer interface therapeutics, has marked a significant milestone by acquiring $50 million in Series B funding. The round was fronted by imec.xpand, known for supporting innovative projects like SOLiTHOR, alongside new backers like EIC Fund, Fond ICO Next Tech, CDTI-Innvierte, and Avançsa. Long-standing supporters such as Asabys Partners and Aliath Bioventures also contributed, enhancing their total funds to $68 million.
This influx of capital is set to accelerate INBRAIN’s ambitious development plans for its graphene-based brain-computer interface therapeutics platform. By marrying cutting-edge bidirectional technology for neural activity modulation with artificial intelligence, INBRAIN aims to reach new heights in the treatment of neurological disorders. The company’s technologies offer groundbreaking resolution in the field.
Strategic Collaborations for Technological Advancement
INBRAIN’s visionary journey is further enhanced by strategic partnerships that propel its technology towards real-world applications. In conjunction with the funding round, INBRAIN has forged a collaboration with Merck KGaA to focus on advancing clinical developments within its therapeutic areas of interest.
Bolstering this collaboration, INBRAIN has also teamed up with imec, a preeminent independent nanoelectronics research hub. This partnership is pivotal for scaling the graphene interface technology commercially. Collectively, these alliances underpin INBRAIN’s commitment to revolutionising neuroscience using the unique properties of graphene, aiming to expand its applications across the nervous system.
Pioneering Graphene-Based Brain Interfaces
Graphene’s unique qualities make it an ideal candidate for neural interfaces. With around 30% of the global population impacted by neural disorders, solutions are in high demand.
Founded in Barcelona in 2019, INBRAIN’s mission is to enhance brain health through minimally invasive neural modulation implants. These utilise graphene’s exceptional electrical and mechanical properties. These lightweight, ultra-thin materials offer unprecedented signal resolution, using sophisticated machine learning algorithms to translate neural signals into therapeutic outcomes.
By enabling high-precision interaction with brainwaves, these implants demonstrate exceptional potential in treating conditions such as epilepsy, Parkinson’s disease, and depression. INBRAIN’s approach marks an innovative leap forward in precision neurology, offering new hope for personalising treatment through neuromodulation.
Restoring Patient Functionality and Mobility
At the heart of INBRAIN’s platform is a commitment to improving patient quality of life. The company’s brain-computer interfaces are designed to optimise time on therapy and restore functionality to patients suffering from neurological challenges.
The platform’s skin-like interface, combined with a dense configuration of up to 1024 contacts, facilitates real-time neural decoding and modulation. Its compact, wireless, rechargeable design enhances usability, providing a seamless experience for both patients and clinicians. Researchers have developed this platform to harness personal patient data efficiently, crafting a bespoke therapeutic approach that strives to maximise patient outcomes.
Breakthroughs in Human Clinical Trials
INBRAIN achieved a significant feat by being awarded the FDA breakthrough device designation for its graphene-neural platform. This recognition endorses its use as an adjunctive treatment for Parkinson’s disease.
A landmark moment in INBRAIN’s progression came with the first human application of its graphene-based brain-computer interface in clinical trials at Salford Royal Hospital, Manchester. This study, focused on evaluating the device’s safety for brain cancer patients, demonstrates graphene’s potential over conventional materials in neural applications.
The success in these trials is a promising step towards broader clinical applications and offers vital insights into the benefits of graphene-based interfaces for neural health. The technology aims to establish new standards in neurologics by integrating meticulous design and advanced materials science.
Industry Perspectives on Innovative Neurotechnology
Carolina Aguilar, CEO of INBRAIN, expressed her vision for the future, highlighting the pivotal nature of their research and its capacity to revolutionise how brain disorders are treated. “We’re shaping the future of brain-computer interfaces,” she said, emphasising the transformative impact of recent financial and technological advances.
Backers also vocalised their excitement. Frank Bulens of imec.xpand envisioned the project as a paradigm shift in treating neurological disorders, predicting that the cutting-edge graphene technology will redefine therapeutic approaches. Investment Director Marcin Nowak highlighted the innovation’s European roots, expressing pride in supporting INBRAIN’s research-to-market transition.
The backing from these prominent figures underscores the advanced capabilities and potential of INBRAIN’s technology, advocating its adoption into mainstream medical practice for enhanced patient care.
INBRAIN’s strides in graphene technology underscore a new era in neurological care, promising substantial enhancements in treatment precision and patient outcomes.
